Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

BACKGROUND: Bone metastasis is a hallmark of advanced prostate cancer. The endothelin pathway has a mechanistic role in bone metastases. Atrasentan, an endothelin receptor antagonist, has reported activity in prostate cancer. We assessed the survival impact of atrasentan in castration resistant pros...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Quinn, David I., Tangen, Catherine M., Hussain, Maha, Lara, Primo N., Goldkorn, Amir, Moinpour, Carol M., Garzotto, Mark G., Mack, Philip C., Carducci, Michael A., Monk, J. Paul, Twardowski, Przemyslaw W., Van Veldhuizen, Peter J., Agarwal, Neeraj, Higano, Celestia S., Vogelzang, Nicholas J., Thompson, Ian M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277263/
https://ncbi.nlm.nih.gov/pubmed/23871417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70294-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados